- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Imugene Ltd (IMU)
Assess today's live Imugene Ltd (IMU) share price, performance and insights using our live Sydney: IMU stock exchange data.
Analyse the historical data and Imugene Ltd share price performance charts on this page. Our technical summary section provides analysis on Imugene Ltd share price buy/sell indicators using real-time data (or discuss the Imugene Ltd (IMU) stock price today with other investors in the Imugene Ltd ASX share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ASX IMU share price (ISIN: AU000000IMU9) to enhance your trading decisions with our free investment tools and resources.
What Is the Imugene Ltd Share Price Today?
The Imugene Ltd share price today is 0.110.
What Is the Stock Symbol for Imugene Ltd
The stock symbol (or 'ticker') for Imugene Ltd is "IMU."
What Stock Exchange Does Imugene Ltd Trade On?
Imugene Ltd is listed and trades on the Sydney stock exchange.
Is Imugene Ltd a Good Stock to Buy?
Determining whether Imugene Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Imugene Ltd share price performance charts on this page. Our technical summary section provides analysis on Imugene Ltd share price buy/sell indicators using real-time data (or discuss the Imugene Ltd (IMU) stock price today with other investors in the Imugene Ltd ASX share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ASX IMU share price (ISIN: AU000000IMU9) to enhance your trading decisions with our free investment tools and resources.
What Is the Imugene Ltd Share Price Today?
The Imugene Ltd share price today is 0.110.
What Is the Stock Symbol for Imugene Ltd
The stock symbol (or 'ticker') for Imugene Ltd is "IMU."
What Stock Exchange Does Imugene Ltd Trade On?
Imugene Ltd is listed and trades on the Sydney stock exchange.
Is Imugene Ltd a Good Stock to Buy?
Determining whether Imugene Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Sydney
Currency in AUD
0.110
-0.005(-4.35%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.110
0.115
52 wk Range
0.016
0.850
IMU is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.1100.115
52 wk Range
0.0160.850
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
IMU Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
0.820
Upside
+645.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.820
(+645.45% Upside)
Earnings
Latest Release
25/02/2026
EPS / Forecast
-0.13 / -1.00
Revenue / Forecast
805.72K / --
Compare IMU to Peers and Sector
Metrics to compare | IMU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMUPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −4.6x | −0.5x | |
PEG Ratio | −0.01 | −0.05 | 0.00 | |
Price/Book | 1.1x | 2.5x | 2.6x | |
Price / LTM Sales | 11.2x | 21.0x | 3.2x | |
Upside (Analyst Target) | - | 165.0% | 48.8% | |
Fair Value Upside | Unlock | −6.4% | 6.9% | Unlock |
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Imugene Ltd (Sydney: IMU) Share Price Today?
The Imugene Ltd stock price today is 0.110 AUD.
What Stock Exchange Does Imugene Ltd (IMU) Trade On?
Imugene Ltd is listed and trades on the Sydney Stock Exchange.
What Is the Ticker (Stock Symbol) for Imugene Ltd?
The stock symbol (also called a 'ticker') for Imugene Ltd is "IMU."
What Is the Current Imugene Ltd Market Capitalisation?
As of today, Imugene Ltd (Sydney: IMU) market cap is 46.380M AUD.
What Is Imugene Ltd's (IMU) Earnings Per Share (TTM)?
The Imugene Ltd EPS is currently -0.229 (Trailing Twelve Months).
When Is the Next Imugene Ltd Earnings Date?
Imugene Ltd's next earnings report will be released on 03/06/2026.
Is IMU a Buy or Sell From a Technical Analyst Perspective?
Based on today's Imugene Ltd moving averages and other technical indicators, the daily buy/sell signal for IMU stock is Strong Sell.
How Many Times Has Imugene Ltd Stock Split?
Imugene Ltd has split 6 times. (See the IMU stock split history page for full effective split date and price information.)
How Many Employees Does Imugene Ltd Have?
Imugene Ltd has 15 employees, based on their latest Companies House report.
What is the current trading status of Imugene Ltd (Sydney: IMU)?
As of 01/05/2026, Imugene Ltd (IMU) is trading at a share price of 0.110 AUD, with a previous close of 0.115 AUD. The stock has fluctuated within a day range of 0.110 AUD to 0.115 AUD, while its 52-week range spans from 0.016 AUD to 0.850 AUD.
What Is Imugene Ltd (IMU) Price Target According to Analysts?
The average 12-month price target for Imugene Ltd is 0.820 AUD, with a high estimate of 0.82 AUD and a low estimate of 0.82 AUD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +645.45% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.